 Simulations Pluss total return overperformed the Dow average for my 67-month test period by 308.05, which is great, and the recent dip is a buying opportunity. Simulations Pluss three-year past CAGR of 18.5 is well above average and will give you great growth with the increasing need to test new drugs faster than before. 